These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 19121451

  • 21. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
    Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J, van Ingen H.
    Circulation; 2009 Jan 27; 119(3):417-25. PubMed ID: 19139391
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnoea activity in patients with essential hypertension and OSA.
    Heitmann J, Greulich T, Reinke C, Koehler U, Vogelmeier C, Becker HF, Schmidt AC, Canisius S.
    Curr Med Res Opin; 2010 Aug 27; 26(8):1925-32. PubMed ID: 20560730
    [Abstract] [Full Text] [Related]

  • 23. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT).
    Frishman WH, Hainer JW, Sugg J, M-FACT Study Group.
    Am J Hypertens; 2006 Apr 27; 19(4):388-95. PubMed ID: 16580575
    [Abstract] [Full Text] [Related]

  • 24. Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial.
    Lewin A, Lasseter KC, Dong F, Whalen JC.
    J Am Soc Hypertens; 2012 Apr 27; 6(3):228-36. PubMed ID: 22421631
    [Abstract] [Full Text] [Related]

  • 25. EVOLVE (nebivolol evaluation for efficacy and safety in the treatment of hypertension) postmarketing surveillance study.
    Faruqui AA.
    J Indian Med Assoc; 2007 May 27; 105(5):272, 274, 276-7. PubMed ID: 17915798
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Differential effects of nebivolol and atenolol on transmitral diastolic filling parameters in patients with essential hypertension.
    Tuncer M, Guntekin U, Gunes Y, Gumrukcuoglu HA, Eryonucu B.
    Adv Ther; 2008 Jun 27; 25(6):619-26. PubMed ID: 18563311
    [Abstract] [Full Text] [Related]

  • 31. Nebivolol: a third-generation beta-adrenergic blocker.
    Veverka A, Nuzum DS, Jolly JL.
    Ann Pharmacother; 2006 Jun 27; 40(7-8):1353-60. PubMed ID: 16822893
    [Abstract] [Full Text] [Related]

  • 32. Nebivolol/hydrochlorothiazide (HCTZ) combination in patients with essential hypertension: a pooled analysis from five non-interventional studies with a focus on diabetic and elderly patients.
    Malacco E.
    Eur Rev Med Pharmacol Sci; 2010 May 27; 14(5):427-34. PubMed ID: 20556921
    [Abstract] [Full Text] [Related]

  • 33. Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD.
    Cazzola M, Matera MG, Ruggeri P, Sanduzzi A, Spicuzza L, Vatrella A, Girbino G.
    Respiration; 2004 May 27; 71(2):159-64. PubMed ID: 15031571
    [Abstract] [Full Text] [Related]

  • 34. Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial.
    Erdoğan O, Ertem B, Altun A.
    Anadolu Kardiyol Derg; 2011 Jun 27; 11(4):310-3. PubMed ID: 21543293
    [Abstract] [Full Text] [Related]

  • 35. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul 27; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 36. Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol.
    Celik T, Yuksel UC, Iyisoy A, Kursaklioglu H, Ozcan O, Kilic S, Ozmen N, Isik E.
    Int J Cardiol; 2007 Mar 20; 116(2):206-11. PubMed ID: 16822563
    [Abstract] [Full Text] [Related]

  • 37. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension.
    Georgescu A, Popov D, Dragan E, Dragomir E, Badila E.
    Eur J Pharmacol; 2007 Sep 10; 570(1-3):149-58. PubMed ID: 17612521
    [Abstract] [Full Text] [Related]

  • 38. An eight-week, multicenter, randomized, double-blind study to evaluate the efficacy and tolerability of fixed-dose amlodipine/benazepril combination in comparison with amlodipine as first-line therapy in chinese patients with mild to moderate hypertension.
    Ueng KC, Lin LC, Voon WC, Lin MC, Liu YB, Su HM, Chang PY, Lin TH, Chen WL, Wu CC, Lai WT, Lin CS.
    Blood Press Suppl; 2008 Jun 10; 1():24-31. PubMed ID: 18705532
    [Abstract] [Full Text] [Related]

  • 39. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment?
    Schellenberg R, Lichtenthal A, Wöhling H, Graf C, Brixius K.
    Headache; 2008 Jan 10; 48(1):118-25. PubMed ID: 18184294
    [Abstract] [Full Text] [Related]

  • 40. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients.
    Lacourcière Y, Arnott W.
    J Hum Hypertens; 1994 Apr 10; 8(4):283-8. PubMed ID: 8021909
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.